Presented on October 4, 2024.

Arthex Biotech presents myotonic dystrophy program, including ATX-01 program for DM1 and an overview of the ArthemiR trial. Click here to learn more about ARTHEx Biotech.

Find the latest updates to the Arthex's ArthemiR Trial, including trial site recruiting status, on ClinicalTrials.gov.

Presenters include:

• Beatriz Llamusi, PhD, Chief Scientific Officer & Co-Founder, Arthex Biotech
• Judy Walker, MD, FRCP(C), Chief Medical Officer, Arthex Biotech

MDF Resources referenced in the Video:

• Toolkits & Publications
• MDF Support Groups
• Digital Academy
• Calendar of Events
• DM Drug Development Pipeline
• Myotonic Dystrophy Family Registry (MDFR)
• 2025 MDF Annual Conference
• Sign up for My Dispatch, our monthly e-newsletter

About Meet the Myotonic Dystrophy Drug Developers

Biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to find all our upcoming Meet the DM Drug Developers dates!